Hey traders, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to roar. Let’s break it down and see if Pfizer could be preparing for a bullish comeback.
Pfizer Inc. ($PFE) — a company that needs no introduction. One of the biggest pharmaceutical players in history, and the one that made sure the world knew its name during the pandemic with the first COVID-19 vaccine. Now, opinions about that vaccine aside — markets don’t care about opinions, news, or headlines. They only care about one thing: imbalances between supply and demand.
And right now, on the weekly timeframe, demand at $24 has officially taken control.
We’ve got a fresh weekly demand imbalance trading between $24.39 and $23.58, and it’s already gained control. This is the largest bullish candlestick in months — a clear reaction showing professional buying pressure stepping in after months of drifting lower.
The beauty of this setup? The risk is under $1, which makes it a tight, well-defined imbalance—a pocket of price where institutions previously bought aggressively.
This imbalance is not a support level — it’s a footprint of institutional buying power. Remember, support is where retail traders dream of price bouncing; demand is where the pros already made it happen.
If you’ve been following my analyses, you already know what comes next — patience. Trading is the art of waiting for the perfect storm: a strong trend, a clear imbalance, and price revisiting that zone.
Emotions are the enemy here. Most traders panic when they see a red candle, while professionals get ready to buy more at wholesale prices. That’s what this new Pfizer demand zone represents — wholesale pricing.
On the weekly timeframe, Pfizer is trending higher. This new demand imbalance aligns perfectly with that bullish momentum.
Price reacted strongly to that zone, showing that buyers are defending it. That’s exactly what we want to see — a solid reaction from a clean, fresh imbalance on a higher timeframe.
Could Pfizer rally from here? It absolutely could — if the weekly demand continues to hold. But remember, this is not about predicting the future; it’s about aligning with probability. And right now, probability is shifting in favour of the bulls.
Pfizer’s chart is telling a clear story: a strong impulsive move, a well-defined weekly demand zone, and a renewed bullish structure. Whether you trade stocks, options, or CFDs, the logic remains the same — the imbalance between buyers and sellers is what moves the market, not the news.
Most traders chase headlines; I chase imbalances.
So, if you want to learn how to read charts like this and plan your trades with surgical precision, make sure to subscribe to my channel and check out the free Supply and Demand course at set-and-forget.com.